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Enhanced LDL oxidation in uremic patients: An additional mechanism
for accelerated atherosclerosis? Since oxidized low-density lipoprotein
(LDL) is more atherogenic than native LDL, LDL oxidation was
investigated in uremic patients who often develop accelerated athero-
genesis. Three groups of uremic patients were studied (10 on predialysis
conservative therapy, II on repetitive hemodialysis, 13 on peritoneal
dialysis) and compared with seventy matched controls. LDL oxidation
was evaluated in all patients as: (i) the susceptibility to in vitro oxidation
(by measuring the resistence to Cu-induced formation of conjugated
dienes), (ii) vitamin E concentration in LDL, and (iii) presence of
plasma anti-oxidized LDL antibodies, expressed as the ratio anti-
0xLDL/anti-nativeLDL antibodies. The lipid profile was studied in all
patients. Vitamin £ concentration did not differ between the various
groups, although LDL from uremic patients appeared more susceptible
to in vitro and in vivo oxidation (as demonstrated by an earlier
generation of conjugated dienes and by the presence of an higher
antibody ratio) compared to control subjects. Subclass analysis of the
different patients revealed that peritoneal dialysis treatment amelio-
rated the oxidation markers. However, a prolonged dialytic treatment
caused a decrease in vitamin E concentration in LDL and increased
their susceptibility to oxidation.
Patients with cronic uremia often develop atherosclerosis
and, in addition, more than 50% of these patients die from
cardiovascular complications [1, 2]. Extensive investigations
have been carried out in order to identify the causes of the
accelerated atherosclerosis detected in uremia. Hyperlipidemia
is frequently seen in patients with renal failure both in the
predialysis and during hemodialysis or peritoneal dialysis [31. In
addition to hypertriglyceridemia [31,which is the most common
abnormality detected, an increase in plasma intermediate-
density lipoprotein (IDL) concentration and a decrease in
high-density lipoprotein (HDL) concentration during renal fail-
ure has been frequently reported [4—6].
The most accepted theory of atherogenesis postulates that
lipoproteins from the bloodstream are taken up by macrophages
in the subendothelial space, leading to the formation of choles-
terol-engulfed cells (foam cells), and they trigger a series of
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biological events ending in the formation of the atherosclerotic
plaque [7]. The arterial narrowing that follows impairs the blood
supply to several organs such as heart, brain, kidney, etc., and
causes the clinical features of the above-mentioned diseases.
Of the various lipoproteins, low-density lipoprotein (LDL) is
most avidly taken up by subendothelial macrophages through a
specific receptor [8]. Studies performed by Goldstein et a!
demonstrated that some chemical modifications of LDL re-
sulted in an enhanced uptake of LDL itself by the so-called
"scavenger receptor" in macrophages [9]. Among the various
modifications that increase LDL uptake by macrophages and
that are likely to occur in vivo, is the derivatization of the LDL
apolipoprotein (apo-B 100) by breakdown products of lipid
peroxides such as malondialdehyde (MDA) and 4-OH-nonenal
(HNE) [10, 11]. Thus free radical- or lypoxygenase-mediated
mechanisms could generate oxidized LDL that would be sub-
sequently taken up by macrophages and would precipitate the
formation of the atherosclerotic plaque. Subsequent investiga-
tions provided evidences that oxidized lipoproteins also cause a
series of biological alterations detected in atherosclerosis [12],
that oxidative modifications of LDL do actually occur in vivo
[13] and reported the presence of oxidized lipids in atheroscle-
rotic plaques [14]. This led to the formulation of the "oxidative
theory of atherosclerosis" hypothesizing that LDL oxidation
would represent a critical step in the developmment and pro-
gression of the disease. This hypothesis has been recently
validated by Salonen et al [15], who reported that the occur-
rence of in vivo markers of LDL oxidation (presence of au-
toantibodies to MDA-LDL) was an independent predictor of
carotid atherosclerosis progression.
Oxidant injury has been implicated in the pathogenesis of
inflammatory, metabolic and toxic diseases and oxidant-
induced alterations of proteins, membranes and DNA have
been detected in some renal disorders such as glomerulonephn-
tis, vasculitis, pyelonephritis and acute or chronic renal failure
[16]. In addition, stimulated polymorphonuclear leukocytes
isolated from uremic patients exhibited an enhanced production
of hydrogen peroxide and other oxygen reactive species [17].
Furthermore, Toborek et al [18] have reported an increased
lipid peroxidation during hemodialysis and proposed a role for
this process in the accelerated progression of atherosclerosis in
patients with renal failure. Based on these observations, it can
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Table 1. Biochemical and demographic parameters and serum lipid profile of the subjects under study
Predialytic
Parameter
Control
subjects(N = 70)
Total uremic
patients(N = 37)
conservative
therapy(N = 11)
Repetitive
hemodialysis(N = 12)
Pentoneal
dialysis(N = 14)
Age years 61.8 23 56.7 2.3 58 4.7 52 4.6 60 2.7
Sex 28M,42F 20M,l7F 4M,7F 7M,5F 9M,5F
Body mass index 24.8 5.2 26.7 6.5 23.5 3 26.9 5.1
Total cholesterol mg/dl 163 9.8 198 8.4a 184 11 174 18 221 l4
LDL cholesterol mg/dI 101 7.6 95.3 5.7 88 11 95 13 93 11
HDL cholesterol mg/dI 50.5 2.7 43 1.8 40 2 41 3 44 3a
Triglycerides mg/dl 91.8 37.2 178 J5 178 34 167 25 200 6
ApoproteinAlmg/dl >110 126±4.5 117±8 117±7 135±6
Apoprotein B mg/dI < 140 142 6.5 136 9 122 14 162 10.5
Results are expressed as mean SE.
a Significantly different from controls, P < 0.01
be assumed that an oxidative stress is likely to take place in the
blood of patients with chronic renal failure.
In this work we investigated the process of LDL oxidation in
uremic patients who were ending conservative therapy or in
dialysis. Data reported indicate that an enhanced oxidation of
LDL occurs in uremic patients and that dialysis treatment (and
especially peritoneal dialysis) temporarily ameliorates the oxi-
dation pattern. We hypothesize that the increased susceptibility
of LDL from uremic patients to oxidation may represent a
critical step in the development of the atherosclerotic disease,
and we envisage a possible therapeutic approach.
Methods
Patients
Three groups of unselected uremic patients have been inves-
tigated: ten predialytic patients on conservative therapy, eleven
on repetitive hemodialysis (3 times a week with a HC03
hemodialysis on cuprophane membranes), thirteen on conven-
tional CAPD treatment, and they were compared with seventy
control subjects (Table 1). The majority of the patients studied
(55%) had a post-inflammatory (glomerulonephritis, pyelone-
phritis, LES) chronic renal failure; nephrolithiasis, polycystic
disease and diabetes mellitus were respectively present in 13%,
13% and 6% of the patients. For three of them, the pathogenesis
of the chronic renal failure was unknown. Hypertension was
present in 38% of the patients and was clinically well-controlled
with an anti-hypertensive therapy using Ca2-channel blockers.
The mean giomerular filtration rate (GFR) for the predialytic
patients was 12 5 mllmin. The adequacy of the dialytic
treatment was evaluated using the KtJV (urea) [19] that ranged
from 1 to 1.2 for hemodialytic patients and from 1.6 to 1.8
(weekly) for CAPD patients. The Kt/V was calculated using a
commercially available computer program. None of the patients
was taking drugs directly affecting the antioxidant and the
lipidic status.
Evaluation of plasma lipid profile
Plasma obtained from EDTA-suppiemented blood (1 mg
EDTA/ml blood) was utilized for measuring lipid parameters.
Cholesterol was assayed using an enzymatic method as total
cholesterol or as HDL-cholesterol in the supernatant obtained
after centrifugation of dextran sulphate-precipitated plasma.
Triglycerides were measured using an enzymatic-colorimetric
method. LDL-cholesterol concentration was calculated from
total and HDL cholesterol and triglyceride levels, using Friede-
wald's formula. Apolipoproteins Al and B were measured using
an immuno-turbidimetric assay.
Measure of LDL oxidation
The experimental protocol described by Esterbauer et al [20]
was employed. Briefly, venous blood was taken from each
patient, after overnight fasting, in polypropilene tubes contain-
ing K-EDTA (final concentration 1 mg EDTA/ml blood), and
plasma was collected after centrifugation. The LDL fraction
was isolated from the whole plasma by high-speed centrifuga-
tion through a KBr discontinuous gradient and collected as the
fraction floating at a density of 1.019 to 1.063 g/ml. EDTA was
then removed by rapid filtration through disposable desalting
columns Econo-Pac 10 DG (Bio-Rad) and LDL was resus-
pended in oxygen-saturated phosphate-buffered saline (10 mrs
Pi, pH 7.2) at a concentration of 0.25 mg LDL mass/ml buffer
(= 50 jsg LDL protein/mi 0.1 pM).
LDL oxidation was then triggered by the addition of 2 tM
CuSO4 and continuously monitored spectrophotometricaily at
234 nm, to follow the formation of conjugated dienes. The
oxidation curve obtained was characterized by two parameters.
The lag-phase (expressed in minutes), that is, the interval
between the addition of CuSO4 and the beginning of the
extensive oxidation, was measured on the basis of the intercept
between the baseline and the tangent to the rapid oxidation
phase. The propagation rate, expressed in changes in absor-
bance (Abs)/min, is the maximal rate of LDL oxidation detected
in the kinetic curve.
Vitamin E determination
Vitamin E in LDL was determined as described [211. Briefly,
LDL were precipitated using ethanol and subsequently vitamin
E was extracted with hexane. The hexane phase was then
evaporated and the residue was dissolved in methanol and
separated by HPLC.
Measure of anti-oxidized and anti-native LDL antibodies
The quantitation of anti-oxidized and anti-native LDL anti-
bodies was performed using an ELISA method. Disposable, 96
well polystyrene plates (Corning) were employed. Antigens for
this assay included native LDL (protected against oxidation by
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EDTA) and oxidized LDL (obtained after extensive oxidation
with 2 M CuSO4). Each well was coated with 10 tg antigen in
PBS for four hours. After removal of the antigen, the remaining
binding sites were blocked using 3% fetal bovine serum in PBS
(coating buffer) for two hours at 37°C.
In the present study, 1:11 dilution of plasma from each
subject was prepared and 220 j.d were added in duplicate to
wells coated with native and oxidized LDL. After two hours
incubation at 37°C, wells were decanted and washed four times
before an appropriate peroxidase-conjugated monoclonal anti-
body specific for IgG (diluted 1:2000) was added. After one hour
incubation at 37°C and extensive washing, the peroxidase
activity was measured using phenylenediamine dihydrochloride
and H202 as revealing reagents.
To calculate antibody titers we used the ratio between the
spectrophotometric reading of anti-oxidized LDL and the anti-
native LDL wells. Using this approach, the spectrophotometric
readings of anti-native LDL wells represent the corresponding
blank of anti-oxLDL wells and minimize the possible detection
of false positive values due to cross reactivity with both LDL
epitopes.
Statistical analysis
All data were statistically analyzed with Student's t-test and
linear regression analysis using the Micro-Cal Origin program
for personal computers. Results are expressed as mean SEM.
Results
Alterations of plasma lipid profile in uremic patients
The plasma lipid profile of the uremic patients is reported in
Table 1. An increase of triglyceride and a decrease of HDL
cholesterol levels were typical features of all the groups of
uremic patients investigated, in agreement with data reported in
literature [1—4]. In addition, patients on peritoneal dialysis had
a higher concentration of total cholesterol and of apolipoprotein
B 100.
LDL oxidation and vitamin E content in uremic patients
The susceptibility of LDL from control subjects and from
uremic patients to oxidation was investigated in vitro. Figure 1
reports a typical trace of in vitro LDL oxidation induced by
CuSO4 and monitored as the formation of conjugated dienes,
and the parameters (lag-phase and propagation rate) utilized for
quantitative estimation. The duration of the lag-phase is a direct
measure of the resistance of LDL to oxidation promoted by
copper, and is related to both the antioxidant content and some
intrinsic properties of LDL, such as the relative abundance of
polyunsaturated fatty acids, cholesterol, etc. On the contrary,
little is known about the biochemical factors controlling the
propagation rate of LDL oxidation. However, based on the
analysis performed on more than 400 individuals investigated in
our laboratory so far, we found a highly significant inverse
correlation between the duration of the lag-phase and the
propagation rate (N = 451, r = —0.67, P < 0.001). Thus, it can
be conceivably argued that an increase of the propagation rate
could be considered as an additional index of enhanced suscep-
tibility of LDL to oxidation.
The lag-phase of LDL oxidation obtained from uremic pa-
tients was significantly lower compared to that observed in
0.2
0
0 60 120 180 240 300 360
Time, minutes
Fig. 1. LDL oxidation profile. In vitro oxidation of LDL was continu-
ously monitored spectrophotometrically at 234 nm to follow the forma-
tion of conjugated dienes after addition of 2 M CuSO4 at time zero. The
lag-phase is the period in which no appreciable oxidation takes place
and is calculated at the intercept between the baseline and the tangent
to the propagation phase. The propagation rate is calculated as the
maximal rate of increase in the absorbance at 234 nm. One typical curve
is shown.
control subjects (119 3.1 mm vs. 142 3.3 mm, P < 0.01;
Table 2). Concomitantly, the propagation rate was markedly
and significantly increased (130 5 Abs 104/min vs. 103 3
Abs• 104/min, P <0.01; Table 2). It has been recently hypoth-
esized that calcium channel blocking drugs could exert an
antioxidant activity on certain tissues and cell compartments
[22]. Since a significant proportion of the patients investigated
in this study was taking these drugs, a subclass analysis was
performed to investigate the influence of this treatment on LDL
oxidation parameters. However, neither the duration of the
lag-phase (120.8 4.4 mm) nor the propagation rate (125.8
5.7 Abs 104/min) differed from those detected in the whole
group of patients.
The enhanced susceptibility of LDL to oxidation was even
increased when data obtained from patients on ending conser-
vative therapy were analyzed and compared with those ob-
tained from the group of patients on peritoneal dialysis. These
patients exhibited a longer lag-phase and a slower propagation
rate (135.8 5.1 mm vs. 109.6 6.06 mm, P < 0.01; 118 6
Abs• 104/min vs. 135 14 Abs' 104/min, P <0.01; Table 2).
Surprisingly, no significant differences were detected as con-
cerning vitamin E concentration in LDL obtained from control
and from the different groups of uremic patients (2.8 0.3
nmol/mg LDL in control subjects, 2.9 0.1 nmollmg LDL in
uremic patients). Assuming a molecular mass of approximately
2,200,000 for LDL, vitamin E concentration detected in this
study in control subjects corresponded to 6.16 0.65 molimol
LDL, a value comparable to those reported in literature [23].
Taken together, these data suggest that LDL from uremic
patients are more prone to oxidation, independently from
vitamin E concentration, and that peritoneal dialysis signifi-
cantly ameliorates this condition.
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A Table 2. Alterations of in vitro LDL oxidation parameters and
vitamin E content in uremic patients
Lag-phase
mm
Propagation rate
Abs 104/min
Vitamin E
nmo!/mg LDL
Control subjects 142 3.3 103 3 2.8 0.3
Uremic patients 119 3.1k 130 5 2.9 0.1
Group A 109 6.06a 135 l4 2.91 0.1
Group B
Group C
119 44a
125.8 51a,b
137 iia
118 6a,b
3.12 0.2
3.0 0.2
LDL were isolated from control and uremic patients and processed as
described in Methods to measure the lag-phase and propagation rate and
to quantitate vitamin E concentration. Group A refers to uremic
patients on conservative therapy; group B refers to uremic patients on
repetitive hemodialysis; group C refers to uremic patients on peritoneal
dialysis.
a Significantly different (P < 0.01) from controls
0 1 2 3 4 5 6
b Significantly different (P < 0.01) from group A
0 1 2 3 4 5 6
Vitamin E, nmol/mg LDL
Fig. 2. Statistical correlation between lag-phase and vitamin E content
of LDL from control subjects (A) and uremic patients (B). LDL were
isolated from control and uremic patients and processed as described in
Methods to measure the lag-phase and to quantitate vitamin E concen-
tration. Equations on the bottom right corner describe the relationship
observed (Y = kX + a). Y: lag-phase (in mm); k: efficacy constant of
vitamin E; X: vitamin E (nmol/mg LDL); a: vitamin E-independent
variable (in mm).
As stated above, the resistance of LDL to oxidation is related
to both the antioxidant content of LDL (mainly vitamin E) and
some antioxidant-independent, intrinsic properties of LDL.
Esterbauer et al have recently adressed the problem of quanti-
fying the relative contribution given by vitamin E content to the
resistance of LDL to oxidation (lag-phase) [20]. This can be
experimentally approached by loading LDL from individual
subjects with various amounts of vitamin E and by subse-
quently measuring the resistance of vitamin E-loaded LDL to
oxidation. A linear relationship is obtained and the curve fitting
is described by the equation
y = kx + a
where y is the lag-phase in minutes, x is vitamin E concentra-
tion, k is the efficacy constant of vitamin E and a is the vitamin
E-independent variable, in minutes.
In the present study, a similar procedure was employed to
analyze the data obtained in control subjects and in uremic
patients, with the assumption that the general formula devel-
oped by Esterbauer et al [23] for LDL from single individuals
loaded with different amounts of vitamin E could also apply to
a LDL isolated from a rather homogeneous group of patients
and containing variable amounts of endogenous vitamin E. As
reported in Figure 2, the two parameters investigated (lag-phase
and vitamin E content) exhibited a linear correlation for both
control subjects and uremic patients. However, the correlation
parameters obtained from curve fitting were markedly different.
The slope of the correlation line (k) was higher in controls (30.2
7.6 vs. 8.44 4.5 minJnmol vitamin E) and the intercept of
the correlation line with the y axis (a) was higher in the uremic
group (94.7 vs. 58.05 mm). In other words, the relative contri-
bution of vitamin E in protecting LDL from oxidation was
lower in uremic patients as compared to control subjects.
Presence of plasma anti-oxidized LDL antibodies in uremic
patients
The oxidation parameters investigated and the data reported
in the previous section refer to the susceptibility of LDL to in
vitro oxidation but they do not give any reliable information on
the oxidation process that is actually occurring in vivo. Since
oxidative modifications of LDL and the formation of MDA-
LDL or HNE-LDL adducts results in a marked change in the
antigenic properties of the LDL molecule [15, 24, 25], it can be
conceivably assumed that a prolonged exposure to oxidized
LDL in vivo could result in the production of specific auto-
antibodies. The detection of anti-oxidized LDL antibodies in
serum or plasma has been taken, indeed, as the biological
signature of the in vivo LDL oxidation [15].
As reported in Figure 3A a marked increase in anti-oxidized
LDL antibody (IgG) titer was detected in plasma of uremic
patients as compared to control subjects (1.6 0.1 vs. 1.2
0.1, P < 0.01). In patients assuming calcium channel blocking
drugs, the anti-oxidized LDL antibody ratio was similar to that
0 0
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oxygen reactive species generated by inflammatory cells. It
thus appears rather suprising that LDL from patients on dialytic
treatment could exhibit an enhanced resistance to oxidation as
compared to LDL from patients on conservative therapy. We
then investigated the effects of dialytic treatment duration on
LDL oxidation and vitamin E content. As reported in Figure 4,
no correlation was found between the lag-phase of in vitro LDL
oxidation or vitamin E content and the length of repetitive
hemodialysis. However, a highly significant negative correla-
tion was found with the duration of peritoneal dialysis, thus
indicating that long-term peritoneal dialysis progressively de-
creased vitamin E content and increased the susceptibility of
LDL to oxidation. On the contrary, short-term peritoneal
dialysis (< 10 months) markedly increased the length of the
lag-phase. Preliminary results obtained on individual uremic
patients before and after short-term peritoneal dialysis revealed
a marked amelioration of LDL susceptibility to oxidation (the
lag-phase increase from 119.5 13.8 to 149.6 19.3 mm, P =
0.02; vitamin E concentration increased from 2.77 0.14 to
3.36 0.26 nmol/mg LDL, P = 0.01;N = 4), further supporting
a direct effect of this dialytic treatment. No correlation was
found between the anti-oxLDL antibody titer and the duration
of peritoneal dialysis or hemodialysis (not shown).
Discussion
The results obtained in this study provide compelling evi-
dence that an increased in vitro and in vivo oxidation of plasma
LDL occurs in uremic patients. This is demonstrated by the
increased susceptibility of isolated LDL to Cu -induced for-
mation of conjugated dienes and by the detection of a high
anti-oxidized LDL antibody titer in plasma.
The methodology employed to promote LDL oxidation in
vitro utilizes low concentrations of CuSO4 that would initiate
peroxidation of LDL lipids through the formation of LO.
according to the reaction:
LOOH + Cu— L0 + OH + Cu
A
0 20 40 60 80 100 120
Age, years
Fig. 3. Presence of anti-oxidized LDL antibodies in plasma of uremic
patients. Plasma was taken from uremic patients and age-matched
control subjects (•) and processed as described in Methods to measure
anti-oxidized LDL antibodies. The antibody titre is expressed as the
ratio between anti-oxidized LDL and anti-native LDL antibodies.
Group A (0) refers to uremic patients on conservative therapy; group
B (A) refers to uremic patients on repetitive hemodialysis; group C (El)
refers to uremic patients on peritoneal dialysis.
detected in the whole group of patients (1.67 0.17). More-
over, dialysis treatment (hemodialysis and peritoneal dialysis)
did not significantly modify the antibody titer.
We have recently reported that the anti-oxidized LDL anti-
body ratio in a group of control subjects progressively declines
during aging [25]. This did not seem to occur in uremic patients,
in which no correlation was found between the antibody ratio
and the age (Fig. 3B).
Effects of the duration of dialytic treatment on LDL oxidation
and vitamin E content
Dialysis, and particularly hemodialysis, represents a contin-
uous inflammatory stimulus and hence a continuous source of
In the experimental conditions employed here Cu + should be
associated with critical binding sites in apo-B 100 [23] and
reduced to Cu by an unknown reducing agent, that has been
proposed to be a preformed LOOH itself [26]. Although this
reaction is thermodynamically unfavored, experimental evi-
dence supports the absolute requirement of preformed LOOH
in initiating Cu-induced peroxidation of LDL lipids [24].
Whichever is the mechanism involved in the initiation of lipid
peroxidation, the subsequent propagation and decomposition of
lipid peroxides will depend on the abundance of polyunsatu-
rated fatty acids and on the concentration and efficiency of
chain-breaking antioxidants. LDL isolated from plasma contain
a wide variety of antioxidants, including a- and y-tochopherol,
carotenoids and ubiquinol- 10 that are sequentially consumed
during the lag-phase of the oxidation process triggered by Cu +
[20]. Vitamin E, however, is the most abundant antioxidant
present (approximately 6 molecules per LDL molecule), and
Halliwell has suggested that is also the only significant antiox-
idant in LDL [271. Additional evidence to this assumption
comes from the demontration that in vitro or in vivo supple-
mentation with vitamin E increases the resistance of LDL to
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phase [21].
The decrease of the lag-phase observed in uremic patients
could then theoretically arise from a reduced concentration of
vitamin E in LDL. This, however, does not seem to be the case
since vitamin E level in LDL from uremic patients is similar to
that present in LDL from control patients. In addition to the
actual concentration of vitamin E, the enhanced susceptibility
of LDL to oxidation could also depend on: (i) a decreased
efficiency of vitamin E, (ii) a selective depletion of other
antioxidants and (iii) alterations of physicochemical properties
of LDL.
Regarding vitamin E efficiency, this can be calculated from
the slope of the correlation between the length of the lag-phase
and the concentration of vitamin E in LDL. In uremic patients,
indeed, the slope is markedly reduced compared to controls. In
other words, much more vitamin E is required in order to obtain
a comparable increase in the length of the lag-phase. Thus
vitamin E in LDL from uremic patients is less efficient than in
LDL from control subjects. Moreover, the concentration of
antioxidants such as carotenoids and ubiquinol-lO in LDL is
about one order of magnitude lower than that of vitamin E [23],
and based on simple stoichiometric calculations they would be
present in only one-tenth of the LDL particles. Thus, it can be
conceivably argued that a selective decrease in their concen-
tration would not play a major role in decreasing the resistance
of LDL from uremic patients to oxidation. In addition, the
measurement of /3-carotene and lycopene in LDL from uremic
patients failed to reveal any appreciable decrease in their
concentration (H. Esterbauer, personal comunication). Further
support of this conclusion comes from the evidence obtained in
this study that the antioxidant (vitamin E)-independent compo-
nent of the lag-phase in LDL from uremic patients is signifi-
cantly higher than in controls. Taken together these findings
suggest that in uremia, major modifications could occur in the
chemical properties of LDL, and these modifications would
increase their susceptibility to oxidation. In agreement with this
view are the demonstrations that a change in protein/lipid ratio
affects the oxidation of LDL from control subjects [28] and that
an increase in PUFA concentration reduces the resistance of
LDL to oxidation [29]. Interestingly, studies performed in
coronary disease patients have revealed the existence of a
negative correlation between the duration of the lag-phase and
the triglyceride concentration in LDL [301. The presence of
high concentrations of triglycerides is one typical feature of
LDL from uremic patients [31] and this would, in part, explain
their increased susceptibility to oxidation.
In addition to kidney transplantation, hemodialysis and pen-
toneal dialysis represent the treatments that definitely amelio-
rate the life expectancy of uremic patients even if, as concern-
ing the LDL oxidation parameters, only peritoneal dialysis
seems to afford a slight although significant improvement. This
could result from: (i) a normalization of the altered chemico-
physical features of LDL that enhance their susceptibility to
oxidation, (ii) an increased efficiency of vitamin E, and (iii) an
increase in vitamin E content. However, none of these hypoth-
eses is validated by experimental data obtained considering the
whole group of patients under pentoneal dialysis. On the other
hand, by itself a prolonged peritoneal dialysis treatment de-
creases both the length of the lag-phase and vitamin E concen-
tration. Thus, the apparent efficiency of a pentoneal dialytic
treatment observed in the whole group would result from the
balance between a short-term improvement of LDL oxidation
parameters and a progressive consuption of vitamin E itself.
A Hemodialysis B Peritoneal dialysis
r:0.703
P< 0.01
5
4
3
2
1
0 100 200 0 50 100 150
Treatment, months Treatment, months
C Hemodialysis D Peritoneal dialysis
r:0.137
. P>0.1 S
•
•
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0 50 100 150
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Fig. 4. Correlation between the duration of
dialytic treatment and the lag-phase of in
vitro LDL oxidation or vitamin E content. The
length of the lag-phase and the concentration
of vitamin E in LDL is plotted against the
duration of dialytic treatment in patients
undergoing repetitive hemodialysis or
peritoneal dialysis.
Cu -induced oxidation and prolongs the length of the lag-
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Little is known about the inefficiency of hemodialysis in pro-
viding significant protection against LDL oxidation, although
the enhanced oxidative stress detected in this conditions could
play a role. Clinical and experimental investigations are in
progress in our laboratory. Evidence indicates that LDL oxi-
dation may play a role in atherogenesis. It includes, for in-
stance, the detection of oxidized lipids in the atherosclerotic
plaque [32] and the demonstration of oxidized LDL [13] and
anti-oxidized LDL autoantibodies [15] in plasma of atheroscle-
rotic patients. Furthermore, a treatment with an antioxidant
drug (probucol) has been reported to reduce the extent of the
atherosclerotic lesions and their progression in rabbits [33].
Based on these observations, we can hypothesize that, in
addition to the detected disorders of lipid metabolism, the
enhanced in vitro and in vivo LDL oxidation observed in uremic
patients could play a relevant role in the overall process of
atherosclerosis.
Since LDL oxidation results from the balance between the
pro-oxidant stimuli on one hand and antioxidant defences on
the other, it could be theoretically possible to interfere with the
oxidation process by increasing the antioxidant defenses. Two
major classes of antioxidants are now pharmacologically avail-
able for medical treatment, namely lipid-soluble and water-
soluble antioxidants. Among the former is vitamin E, whose
oral supplementation has been demonstrated to increase the
resistence of LDL to oxidation in a group or normal volunteers
[21]. However, the efficiency of vitamin E in uremic patients is
decreased as compared to control subjects (this study), and thus
relatively high doses of vitamin E are likely to be necessary to
get a significant protection of LDL. Alternatively, water-solu-
ble antioxidants, such as vitamin C, could be given, due to the
effect of ascorbate in re-reducing oxidized vitamin E [34]. In
conclusion, it can be postulated that, in addition to the phar-
macological correction of lipid disorders, an antioxidant regi-
men with drugs efficiently protecting against LDL oxidation
would provide a powerful strategy for delaying the onset of the
irreversible atherosclerotic disease in uremic patients.
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